FindTrial
Sign In

Efficacy and safety of oral sildenafil in the treatment of pediatric lymphatic malformations in China

Sildenafil in the treatment of pediatric lymphatic malformations

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OPC-16008702
Enrollment
Unknown
Registered
2016-06-22
Start date
2014-05-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric lymphatic malformations

Interventions

Sildenafil-treated group:oral sildenafil

Sponsors

Beijing Children's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: under 9 years old, diagnosed of LMs based on clinical and radiographic criteria with lesions located at any part of the body, had indications for treatment and guardians desired for therapy.

Exclusion criteria

Exclusion criteria: Patients with hypertension, heart problems, renal diseases, life-threatening airway obstruction or allergy to sildenafil were excluded from the study

Design outcomes

Primary

MeasureTime frame
MRI images;—

Countries

China

Contacts

Public ContactXin Ni

Beijing Children's Hospital

Nixin@bch.com.cn+86 010 59616393

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026